{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:29:19Z","timestamp":1767896959807,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004913","name":"Universit\u00e0 degli Studi di Palermo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD) is an autoimmune demyelinating disorder of the central nervous system (CNS) which usually occurs with recurrent optic neuritis, transverse myelitis, acute disseminating encephalomyelitis, or brainstem encephalitis. To date, the anti-CD 20 drug rituximab (RTX) is employed in MOGAD although some authors reported the efficacy of Tocilizumab (TCZ) in refractory patients. We present the case of a woman affected by refractory MOGAD who was treated with TCZ after therapy with RTX had failed to prevent relapses. We also conducted a current literature review on TCZ use in MOGAD. A 57-year-old Caucasian woman affected by MOGAD with severe motor impairment and cognitive dysfunction was treated from 2020 to February 2022 with RTX. However, she experienced progressive clinical and cognitive worsening associated with white matter lesions mimicking leukodystrophy. In February 2022, the patient started therapy with TCZ administered with improvement of cognitive performance, walking ability, and brainstem functions. During TCZ, our patient reached the condition of NEDA-3 (no relapse, no increase in disability, no MRI activity on neuroimaging follow-up performed in September 2023). Moreover, the patient experienced paucisymptomatic SARS-CoV-2 infection that did not modify TCZ schedule. To date, there are few evidence on the efficacy and safety of TCZ in MOGAD. However, all the reviewed cases showed that TCZ represents an effective therapy in drug-resistant MOGAD. Our case highlights the efficacy of TCZ in drug resistant MOGAD and strengthens previous reports of TCZ safety and efficacy in MOGAD.<\/jats:p>","DOI":"10.1007\/s10072-023-07189-7","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T08:01:52Z","timestamp":1701072112000},"page":"1429-1436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tocilizumab treatment in MOGAD: a case report and literature review"],"prefix":"10.1007","volume":"45","author":[{"given":"Giuseppe","family":"Schir\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Iacono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Andolina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2516-1567","authenticated-orcid":false,"given":"Paolo","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"issue":"3","key":"7189_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/WCO.0000000000000813","volume":"33","author":"S Mader","year":"2020","unstructured":"Mader S, K\u00fcmpfel T, Meinl E (2020) Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. Curr Opin Neurol 33(3):362\u2013371. https:\/\/doi.org\/10.1097\/WCO.0000000000000813","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"7189_CR2","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","volume":"95","author":"JJ Chen","year":"2020","unstructured":"Chen JJ, Eoin P, Flanagan M, Bhatti T, Jitprapaikulsan J, Dubey D, Alfonso S, Chiriboga L, Fryer JP et al (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95(2):e111. https:\/\/doi.org\/10.1212\/WNL.0000000000009758","journal-title":"Neurology"},{"key":"7189_CR3","doi-asserted-by":"publisher","unstructured":"Nepal G, Kharel S, Coghlan MA, Rayamajhi P, Ojha R (2022) Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-Associated Disorders (MOGAD): A Systematic Review and Meta-Analysis. J Neuroimmunol 364. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577812","DOI":"10.1016\/j.jneuroim.2022.577812"},{"key":"7189_CR4","doi-asserted-by":"publisher","unstructured":"Rothaug M, Becker-Pauly C, Rose-John S(2016) The role of interleukin-6 signaling in nervous tissue, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Volume 1863, Issue 6, Part A, Pages 1218-1227.https:\/\/doi.org\/10.1016\/j.bbamcr.2016.03.018 (ISSN 0167-4889)","DOI":"10.1016\/j.bbamcr.2016.03.018"},{"issue":"9","key":"7189_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","volume":"20","author":"R Marignier","year":"2021","unstructured":"Marignier R, Yael Hacohen Y, Cobo-Calvow A et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20(9):762\u2013772. https:\/\/doi.org\/10.1016\/S1474-4422(21)00218-0","journal-title":"Lancet Neurol"},{"key":"7189_CR6","doi-asserted-by":"publisher","unstructured":"Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, Hayward-K\u00f6nnecke H, Schippling S, Rommer PS, Kornek B, Zrzavy T, Biotti D, Ciron J, Audoin B, Berthele A, Giglhuber K, Zephir H, K\u00fcmpfel T, Berger R, R\u00f6ther J, H\u00e4u\u00dfler V, Stellmann JP, Whittam D, Jacob A, Kraemer M, Gueguen A, Deschamps R, Bayas A, H\u00fcmmert MW, Trebst C, Haarmann A, Jarius S, Wildemann B, Grothe M, Siebert N, Ruprecht K, Paul F, Collongues N, Marignier R, Levy M, Karenfort M, Deppe M, Albrecht P, Hellwig K, Gold R, Hartung HP, Meuth SG, Kleiter I, Aktas O (2021) Neuromyelitis Optica Study Group (NEMOS). Neurol Neuroimmunol Neuroinflamm 9(1):e1100. https:\/\/doi.org\/10.1212\/NXI.0000000000001100","DOI":"10.1212\/NXI.0000000000001100"},{"key":"7189_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.msard.2018.11.012","volume":"27","author":"G Novi","year":"2019","unstructured":"Novi G, Gastaldi M, Franciotta D, Pesce G, Benedetti L, Uccelli A (2019) Tocilizumab in MOG-antibody spectrum disorder: a case report. Mult Scler Relat Disord 27:312\u2013314. https:\/\/doi.org\/10.1016\/j.msard.2018.11.012","journal-title":"Mult Scler Relat Disord"},{"issue":"16","key":"7189_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1212\/WNL.0000000000007312","volume":"92","author":"Helen Hayward-Koennecke","year":"2019","unstructured":"Hayward-Koennecke Helen, Reindl Markus, Martin Roland, Schippling Sven (2019) Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis. Neurology 92(16):765\u2013767. https:\/\/doi.org\/10.1212\/WNL.0000000000007312","journal-title":"Neurology"},{"key":"7189_CR9","doi-asserted-by":"publisher","unstructured":"Rigal J, Pugnet G, Ciron J, L\u00e9pine Z, Biotti D (2020) Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series. Mult Scler Relat Disord 46. https:\/\/doi.org\/10.1016\/j.msard.2020.102483","DOI":"10.1016\/j.msard.2020.102483"},{"key":"7189_CR10","doi-asserted-by":"publisher","unstructured":"Masuccio FG, Lo Re M, Bertolotto A, Capobianco M, Solaro C (2020) Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment. Mult Scler Relat Disord 46. https:\/\/doi.org\/10.1016\/J.MSARD.2020.102592","DOI":"10.1016\/J.MSARD.2020.102592"},{"key":"7189_CR11","doi-asserted-by":"publisher","unstructured":"Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM (2021) Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review. Mult Scler Relat Disord 48. https:\/\/doi.org\/10.1016\/J.MSARD.2020.102696","DOI":"10.1016\/J.MSARD.2020.102696"},{"key":"7189_CR12","doi-asserted-by":"publisher","unstructured":"Escol\u00e0 JK, Deuschl C, Junker A, Dusse F, Pul R, Kleinschnitz C, K\u00f6hrmann M, Frank B (2022) MOG antibody\u2013associated encephalomyelitis mimicking bacterial following ChAdOx1 NCoV-19 vaccination: a case. Ther Adv Neurol Disord 15. https:\/\/doi.org\/10.1177\/17562864211070684","DOI":"10.1177\/17562864211070684"},{"key":"7189_CR13","doi-asserted-by":"publisher","unstructured":"Nagahata K, Suzuki S, Yokochi R, Nei Y,\u00a0 Hagino N (2022) \u201cRecurrent optic perineuritis with myelin oligodendrocyte glycoprotein antibody-associated disease complicated with granulomatous polyangiitis.\u201d Cureus 14(5). https:\/\/doi.org\/10.7759\/CUREUS.25239","DOI":"10.7759\/CUREUS.25239"},{"key":"7189_CR14","doi-asserted-by":"publisher","unstructured":"Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, Tubridy N, Boggild M (2012) Does natalizumab therapy worsen neuromyelitis optica? Neurology 79(10):1065\u20131066. https:\/\/doi.org\/10.1212\/WNL.0B013E31826845FE","DOI":"10.1212\/WNL.0B013E31826845FE"},{"issue":"8","key":"7189_CR15","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/ARCHNEUROL.2010.188","volume":"67","author":"J Palace","year":"2010","unstructured":"Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67(8):1016\u20131017. https:\/\/doi.org\/10.1001\/ARCHNEUROL.2010.188","journal-title":"Arch Neurol"},{"key":"7189_CR16","doi-asserted-by":"publisher","unstructured":"Kleiter I, Hellwig K, Berthele A, K\u00fcmpfel T, Linker RA, Hartung HP, Paul F, Aktas O (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69(2):239\u2013245. https:\/\/doi.org\/10.1001\/ARCHNEUROL.2011.216","DOI":"10.1001\/ARCHNEUROL.2011.216"},{"key":"7189_CR17","doi-asserted-by":"publisher","unstructured":"Hacohen Y, Rossor T, Mankad K, Chong Wk, Lux A, Wassmer E, Lim M, Barkhof F, Ciccarelli O, Hemingway C (2018) \u2018Leukodystrophy-like\u2019 phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. Dev Med Child Neurol 60(4):417\u201323. https:\/\/doi.org\/10.1111\/DMCN.13649","DOI":"10.1111\/DMCN.13649"},{"key":"7189_CR18","doi-asserted-by":"publisher","unstructured":"Wang J, Qiu Z, Li D, Yang X, Ding Y, Gao L, Liu A et al (2021) Clinical and imaging features of patients with encephalitic symptoms and myelin oligodendrocyte glycoprotein antibodies. Front Immunol 12:3912. https:\/\/doi.org\/10.3389\/FIMMU.2021.722404\/BIBTEX","DOI":"10.3389\/FIMMU.2021.722404\/BIBTEX"},{"issue":"15","key":"7189_CR19","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJM198410113111504","volume":"311","author":"R Eldridge","year":"1984","unstructured":"Eldridge R, Anayiotos CP, Schlesinger S, Cowen D, Bever C, Patronas N, McFarland H (1984) Hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. N Engl J Med 311(15):948\u2013953. https:\/\/doi.org\/10.1056\/NEJM198410113111504","journal-title":"N Engl J Med"},{"issue":"8","key":"7189_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/ARCHNEUR.1994.00540200033013","volume":"51","author":"JD Schwankhaus","year":"1994","unstructured":"Schwankhaus JD, Katz DA, Eldridge R, Schlesinger S, Mcfarland H (1994) Clinical and pathological features of an autosomal dominant, adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. Arch Neurol 51(8):757\u2013766. https:\/\/doi.org\/10.1001\/ARCHNEUR.1994.00540200033013","journal-title":"Arch Neurol"},{"issue":"2","key":"7189_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/ALL.14657","volume":"76","author":"Yd Gao","year":"2021","unstructured":"Gao Yd, Ding M, Dong X, Jj Zhang, Azkur AK, Azkur D, Gan H et al (2021) Risk factors for severe and critically Ill COVID-19 patients: a review. Allergy 76(2):428\u201355. https:\/\/doi.org\/10.1111\/ALL.14657","journal-title":"Allergy"},{"issue":"8","key":"7189_CR22","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","volume":"2","author":"G Guaraldi","year":"2020","unstructured":"Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E et al (2020) Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2(8):e474. https:\/\/doi.org\/10.1016\/S2665-9913(20)30173-9","journal-title":"Lancet Rheumatol"},{"issue":"15","key":"7189_CR23","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1002\/CAM4.4659","volume":"11","author":"K Mortezaee","year":"2022","unstructured":"Mortezaee K, Majidpoor J (2022) Checkpoint inhibitor\/interleukin-based combination therapy of cancer. Cancer Med 11(15):2934. https:\/\/doi.org\/10.1002\/CAM4.4659","journal-title":"Cancer Med"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07189-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07189-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T07:26:53Z","timestamp":1710487613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07189-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["7189"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07189-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"A written informed consent was signed by the patient for the standard diagnostic procedures and therapy. This consent included also the permit to use anonymized data for research purpose. A specific approval was also obtained by the local ethical committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}}]}}